3. (Thrice Amended) An isolated polypeptide having an amino acid sequence of natural human Fas ligand wherein all of the 8th amino acid to 69th amino acid residues as measured from N terminal end are deleted, 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted, and at least one amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residues from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted.

6. (Twice Amended) A soluble Fas ligand which inhibits Fas-mediated apoptosis and which comprises the amino acid sequence represented from Gln of the 130th amino acid to C terminal amino acid residue as measured from N-terminal end of natural human Fas ligand.

10. (Thrice amended) An isolated polypeptide having an amino acid sequence of natural human Fas ligand wherein the 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted, and at least one amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residue from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted, wherein said polypeptide has membrane binding activity and induces Fas-mediated apoptotic activity.

11. (Thrice amended) An isolated polypeptide having an amino acid sequence of natural human Fas ligand wherein all of the 8th amino acid to 69th amino acid residues as measured from N terminal end are deleted, 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted, and at least one amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residues from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted, wherein said polypeptide has membrane binding activity and induces Fas-mediated apoptotic activity.

Please add the following new claim 12.

12. An isolated peptide having an amino acid sequence of natural human Fas ligand wherein at least four amino acid residues, including 128th and 131st amino acid residues are continuously deleted from the 111th amino acid to the 133rd amino acid residues as measured from N terminal end.